<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03697681</url>
  </required_header>
  <id_info>
    <org_study_id>4-2018-0754</org_study_id>
    <nct_id>NCT03697681</nct_id>
  </id_info>
  <brief_title>Protective Effect of Tranexamic Acid on Shedding of the Endothelial Glycocalyx in Patients Undergoing Spinal Fusion Surgery</brief_title>
  <official_title>Protective Effect of Tranexamic Acid on Shedding of the Endothelial Glycocalyx in Patients Undergoing Spinal Fusion Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to determine whether the administration of tranexamic acid in
      patients undergoing lumbar spinal fusion surgery can inhibit damage in endothelial glycocalyx
      layer. As a prospective double blinded randomized placebo-controlled trial, the investigators
      detect and compare the changes in concentrations of serum syndecan-1 and heparan sulfate
      before and after surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 16, 2018</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A Randomized, Double-Blinded, Placebo-Controlled Trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>triple blinded (Participant, Care Provider, investigator)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>base blood concentration of syndecan-1, heparan sulfate</measure>
    <time_frame>within 1 hour before surgery(base concentration)</time_frame>
    <description>preoperative baseline serum levels of syndecan-1 and heparan sulfate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>blood concentration of syndecan-1, heparan sulfate at the end of the surgery</measure>
    <time_frame>within 5 minutes after the end of surgery (when thd surgical drape is removed)</time_frame>
    <description>blood concentration of syndecan-1, heparan sulfate at the end of the surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>blood concentration of syndecan-1, heparan sulfate at 2 hours after surgery</measure>
    <time_frame>2 hours after the end of surgery</time_frame>
    <description>blood concentration of syndecan-1, heparan sulfate at 2 hours after surgery</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Posterior Lumbar Spinal Fusion Surgery</condition>
  <arm_group>
    <arm_group_label>Glutamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous glutamine infusion perioperatively for 18 hours (8 hours before surgery and 10 hours after induction of anesthesia)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic acid</intervention_name>
    <description>Intravenous infusion of Tranexamic acid(mixed with normal saline) at the dose of 10mg/kg(body weight) for 20 min after induction of anesthesia and then administration another 1mg/kg/hr(body weight) of Tranexamic acid(mixed with normal saline) until the end of the operation.</description>
    <arm_group_label>Glutamine</arm_group_label>
    <other_name>glutamine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% NaCl (normal saline)</intervention_name>
    <description>The same amount of normal saline solution without the addition of tranexamic acid is administered in the same manner as the experimental group(Tranexamic acid intervention group).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients with between 30 and 80 years scheduled for posterior lumbar spinal
             fusion surgery.

        Exclusion Criteria:

          -  emergency surgery

          -  patients unable to make their own decisions, illiterate, foreigners

          -  Allergy / hypersensitivity to Tranexamic acid

          -  Current or past history or thrombosis / thromboembolism

          -  patients who are taking oral contraceptives

          -  Patients with renal insufficiency (eGFR 60 ml / min / 1.73 m 2 or less)

          -  Patients receiving anticoagulants

          -  pregnant and lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong Seon Choi, MD, Ph.D</last_name>
      <phone>82-2-2227-3556</phone>
      <email>yschoi@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>October 1, 2018</study_first_submitted>
  <study_first_submitted_qc>October 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2018</study_first_posted>
  <last_update_submitted>May 7, 2019</last_update_submitted>
  <last_update_submitted_qc>May 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

